CYTHW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Jun 2024 @ 16:00):
Our systems believe the stock currently is undervalued by 9.05% compare to its pairs and should correct upwards.

Stats
Today's Volume	663
Average Volume	661
Market Cap	32.01M
EPS	$-0.150 ( Q1 \| 2024-05-15 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 30.78
ATR14	$0 (0.00%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Insider Trading

Date	Person	Action	Amount	type
2023-12-27	Cross Shawn	Buy	88 910	Stock Option (Right to buy)
2023-12-27	Cross Shawn	Buy	72 606	Common Stock
2023-12-27	Cross Shawn	Sell	0	Common Stock
2023-11-28	Conkling William	Buy	7 466	Common Stock
2023-11-28	Ostronic Francis Patrick	Buy	10 262	Common Stock

INSIDER POWER
50.76
Last 65 transactions
Buy: 15 920 013 \| Sell: 5 479 045

Correlation (AI algo v.1.1b): Undervalued: 9.05% $0.262 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Cyclo Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cyclo Therapeutics, Inc. Financials

Annual	2023
Revenue:	$1.08M
Gross Profit:	$-2.41M (-223.91 %)
EPS:	$-1.230

FY	2023
Revenue:	$1.08M
Gross Profit:	$-2.41M (-223.91 %)
EPS:	$-1.230

FY	2022
Revenue:	$1.38M
Gross Profit:	$1.24M (89.90 %)
EPS:	$-1.810

FY	2021
Revenue:	$1.59M
Gross Profit:	$1.43M (90.16 %)
EPS:	$0

Financial Reports:

No articles found.

Cyclo Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product pipeline include Trappsol Cyclo, which treats Neimann-Pick Type C disease and Alzheimer\'s disease. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.